Fierce Biotech

BMS removes 2 clinical programs from pipeline, one from Mirati and another from Exscientia

Bristol Myers Squibb is shedding two clinical programs, one from its 2023 Mirati buyout and another from a partnership with U ...
Fierce Pharma

BMS' hyped schizophrenia launch Cobenfy delivers so-so launch year as execs map plan for future

During BMS’ earnings call Thursday, CEO Chris Boerner, Ph.D., described Cobenfy as “delivering steady growth.” But the first-in-class drug still has a long way to go to fulfill its promise as a ...
GEN

Moffitt Cancer Center Joins BMS’ Immuno-Oncology Program

Bristol-Myers Squibb (BMS) and Moffitt Cancer Center joined forces today as part of BMS’s Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S. The I-O RPM program is a ...
GPS World

NGS 2018 GPS on BMs program in support of NAPGD2022 — Part 5

My last column highlighted two components of the North American-Pacific Vertical Datum of 2022 (NAPGD2022) — the geoid undulation model of GEOID2022 and gravity model of GRAV2022. It expressed that ...
GPS World

NGS 2018 GPS on BMs program in support of NAPGD2022 — Part 7

My last column described the National Geodetic Survey’s (NGS) GPS on Bench Marks (BM) 2018 interactive web map, and provided an update and status report on stations observed in support of the 2018 GPS ...